The stock of Repros Therapeutics Inc (NASDAQ:RPRX) is a huge mover today! About 540,329 shares traded hands or 171.38% up from the average. Repros Therapeutics Inc (NASDAQ:RPRX) has declined 16.44% since April 13, 2016 and is downtrending. It has underperformed by 20.37% the S&P500.
The move comes after 8 months positive chart setup for the $49.81M company. It was reported on Nov, 15 by Barchart.com. We have $5.07 PT which if reached, will make NASDAQ:RPRX worth $83.68M more.
Repros Therapeutics Inc (NASDAQ:RPRX) Ratings Coverage
Out of 3 analysts covering Repros Therapeutics (NASDAQ:RPRX), 0 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 0 are positive. Repros Therapeutics has been the topic of 4 analyst reports since August 20, 2015 according to StockzIntelligence Inc. The rating was downgraded by Brean Capital to “Hold” on Friday, October 30. The rating was downgraded by Bank of America on Friday, October 30 to “Underperform”. The stock of Repros Therapeutics Inc (NASDAQ:RPRX) has “Hold” rating given on Thursday, August 20 by Zacks. Ladenburg Thalmann downgraded the shares of RPRX in a report on Friday, October 30 to “Neutral” rating.
According to Zacks Investment Research, “Zonagen Inc. is a biopharmaceutical company engaged in the development of products for the human reproductive system, including sexual dysfunction, vaccine adjuvants, products for fertility and female health as well as urological applications, specifically prostate cancer. Zonagen’s products to treat sexual dysfunction all incorporate phentolamine mesylate, an alpha-adrenergic blocker, as the active agent. Zonagen’s lead product, VASOMAX(R), is a rapidly disintegrating oral formulation of phentolamine for the treatment of male erectile dysfunction.”
Insitutional Activity: The institutional sentiment decreased to 0.28 in Q2 2016. Its down 0.22, from 0.5 in 2016Q1. The ratio fall, as 16 funds sold all Repros Therapeutics Inc shares owned while 13 reduced positions. 3 funds bought stakes while 5 increased positions. They now own 5.35 million shares or 31.60% less from 7.82 million shares in 2016Q1.
Northern Trust Corp has 60,305 shares for 0% of their US portfolio. The New York-based Goldman Sachs Grp Inc has invested 0% in Repros Therapeutics Inc (NASDAQ:RPRX). Blackrock Ltd Liability Company holds 0% of its portfolio in Repros Therapeutics Inc (NASDAQ:RPRX) for 4,528 shares. Kistler accumulated 0% or 270 shares. Blackrock Fund Advsr owns 58,542 shares or 0% of their US portfolio. California Pub Employees Retirement Systems holds 0% or 118,000 shares in its portfolio. Walleye Trading Ltd Liability Com reported 900 shares or 0% of all its holdings. Fmr Limited Liability Co, a Massachusetts-based fund reported 1.67 million shares. Baldwin Brothers Ma holds 1,750 shares or 0% of its portfolio. Moreover, Blackrock Institutional Tru Na has 0% invested in Repros Therapeutics Inc (NASDAQ:RPRX) for 674,848 shares. Moreover, Art Advisors has 0% invested in Repros Therapeutics Inc (NASDAQ:RPRX) for 34,315 shares. Deutsche National Bank Ag owns 2,448 shares or 0% of their US portfolio. Fincl Bank Of Montreal Can last reported 0% of its portfolio in the stock. Wells Fargo & Comm Mn holds 0% or 5,400 shares in its portfolio. Bogle Inv Mngmt Lp De reported 98,486 shares or 0.01% of all its holdings.
More important recent Repros Therapeutics Inc (NASDAQ:RPRX) news were published by: Benzinga.com which released: “Repros Therapeutics Higher Off Positive Data For Proellex” on November 15, 2016, also Fool.com published article titled: “Why Repros Therapeutics, Inc. Shares Are Soaring”, Seekingalpha.com published: “Is It All Over For Repros Therapeutics?” on November 23, 2015. More interesting news about Repros Therapeutics Inc (NASDAQ:RPRX) was released by: Quotes.Wsj.com and their article: “News Repros Therapeutics Inc.RPRX” with publication date: February 12, 2011.
RPRX Company Profile
Repros Therapeutics, Inc., incorporated on August 20, 1987, is a biopharmaceutical firm focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. Through its clinical program, the Company is focused on conducting a Phase IIb study for low dose oral Proellex in the treatment of uterine fibroids; conducting a Phase IIb vaginal administration study for Proellex in the treatment of uterine fibroids; conducting a Phase II study for low dose oral Proellex for the treatment of endometriosis, and conducting a Phase II proof of concept study for enclomiphene for the treatment of secondary hypogonadism.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.